The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial
Abstract
CONTEXT: Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. OBJECTIVE: To compare the efficacy and safety of rimonabant with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic risk factors over 2 years. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial of 3045 obese (body mass index > or =30) or overweight (body mass index >27 and treated or untreated hypertension or dyslipidemia) adult patients at 64 US and 8 Canadian clinical research centers from August 2001 to April 2004. INTERVENTION: After a 4-week single-blind placebo plus diet (600 kcal/d deficit) run-in period, patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were rerandomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2. MAIN OUTCOME MEASURES: Body weight change over year 1 and prevention of weight regain during year 2. Additional efficacy measures included changes in waist circumference, plasma lipid levels, and other cardiometabolic risk factors. RESULTS: At year 1, the completion rate was 309 (51%) patients in the placebo group, 620 (51%) patients in the 5 mg of rimonabant group, and 673 (55%) patients in the 20 mg of rimonabant group. Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (-6.3 [0.2] kg vs -1.6 [0.2] kg; P<.001), waist circumference (-6.1 [0.2] cm vs -2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, -5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001). Patients who were switched from the 20 mg of rimonabant group to the placebo group during year 2 experienced weight regain while those who continued to receive 20 mg of rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors. Use of different imputation methods to account for the high rate of dropouts in all 3 groups yielded similar results. Rimonabant was generally well tolerated; the most common drug-related adverse event was nausea (11.2% for the 20 mg of rimonabant group vs 5.8% for the placebo group). CONCLUSIONS: In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study. Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00029861.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
A biometric study of basal metabolism in man
Harris, J. A., & Benedict, F. G. (2014) · Medical Entomology and Zoology · Cited by 1,847
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“During the 2nd year, rimonabant-treated patients retained the improvements achieved during the 1st year, whereas those who switched to placebo regained their original weight (Pi-Sunyer et al., 2006).”
BackgroundAuthors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
Consensus on infertility treatment related to polycystic ovary syndrome
(2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.09.041 · Cited by 730
Behavioral treatment of obesity
Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.006 · Cited by 636
Hypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624
Rapezzi, C., Biagini, E., & Branzi, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm498 · Cited by 595
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 593
Salas-Salvadó, J., Rubio, M. A., Barbany, M., & Moreno, B. (2007) · Medicina Clínica · doi:10.1016/s0025-7753(07)72531-9 · Cited by 571
Vuppalanchi, R., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22603 · Cited by 563
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Blüher, M., Engeli, S., Klöting, N., Berndt, J., Fasshauer, M., Bátkai, S., Pacher, P., Schön, M. R., Jordan, J., & Stumvoll, M. (2006) · Diabetes · doi:10.2337/db06-0812 · Cited by 530
Obesity and Bariatric Surgery Drive Epigenetic Variation of Spermatozoa in Humans
Donkin, I., Versteyhe, S., Ingerslev, L. R., Qian, K., Mechta, M., Nordkap, L., Mortensen, B., Appel, E. V. R., Jørgensen, N., Kristiansen, V. B., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.11.004 · Cited by 527
Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease
Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., & Després, J.-P. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.110320 · Cited by 490
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, S., Marsicano, G., Lutz, B., Buettner, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34827 · Cited by 458
Tam, J., Vemuri, V. K., Liu, J., Bátkai, S., Mukhopadhyay, B., Godlewski, G., Osei-Hyiaman, D., Ohnuma, S., Ambudkar, S. V., Pickel, J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42551 · Cited by 454
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.130 · Cited by 439
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Lifestyle modification for the management of obesity
Wadden, T. A., Butryn, M. L., & Wilson, C. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.051 · Cited by 406
Nissen, S. E., Nicholls, S. J., Wolski, K., Rodés-Cabau, J., Cannon, C. P., Deanfield, J. E., Després, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1547 · Cited by 403
Adipose Tissue and Atherosclerosis: Exploring the Connection
Fantuzzi, G., & Mazzone, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.106.131755 · Cited by 384
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Metabolic syndrome and cardiovascular disease
Qiao, Q., Gao, W., Zhang, L., Nyamdorj, R., & Tuomilehto, J. (2007) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/000456307780480963 · Cited by 376
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 367
Endocannabinoids and the control of energy balance
Matias, I., & Di Marzo, V. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.11.006 · Cited by 365
Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms
Buettner, C., Muse, E. D., Cheng, A., Chen, L., Scherer, T., Pocai, A., Su, K., Cheng, B., Li, X., Harvey-White, J., et al. (2008) · Nature Medicine · doi:10.1038/nm1775 · Cited by 342
Gary-Bobo, M., Elachouri, G., Gallas, J. F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., et al. (2007) · Hepatology · doi:10.1002/hep.21641 · Cited by 304
Cannabinoid Hyperemesis Syndrome
A. Galli, J., Andari Sawaya, R., & K. Friedenberg, F. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104040241 · Cited by 303
Bult, M. J. F., van Dalen, T., & Muller, A. F. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0145 · Cited by 301
Gut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 287
The endocannabinoid system in obesity and type 2 diabetes
Di Marzo, V. (2008) · Diabetologia · doi:10.1007/s00125-008-1048-2 · Cited by 281
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 276
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Regulation of nausea and vomiting by cannabinoids
Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01176.x · Cited by 268
Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60935-x · Cited by 266
Bessesen, D. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0520 · Cited by 257
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Sam, A. H., Salem, V., & Ghatei, M. A. (2011) · Journal of Obesity · doi:10.1155/2011/432607 · Cited by 230
Gorzalka, B. B., Hill, M. N., & Hillard, C. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.004 · Cited by 211
Treatment of nausea and vomiting: Gaps in our knowledge
Sanger, G. J., & Andrews, P. L. R. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.07.009 · Cited by 209
Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Factors associated with weight loss after gastric bypass
Campos, G. M. (2008) · Archives of Surgery · doi:10.1001/archsurg.143.9.877 · Cited by 172
A review of web-based weight loss interventions in adults
Arem, H., & Irwin, M. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00787.x · Cited by 172
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rössner, S., Hanotin, C., & Ziegler, O. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn076 · Cited by 156
Digenio, A. G., Mancuso, J. P., Gerber, R. A., & Dvorak, R. V. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-4-200902170-00006 · Cited by 148
Van Laere, K., Goffin, K., Casteels, C., Dupont, P., Mortelmans, L., de Hoon, J., & Bormans, G. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.053 · Cited by 142
Ryan, D. H. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.508 · Cited by 143
Behavior therapy for obesity: where are we now?
Sarwer, D. B., von Sydow Green, A., Vetter, M. L., & Wadden, T. A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832f5a79 · Cited by 120
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Melnikova, I., & Wages, D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2037 · Cited by 110
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management
Farshchi, H., Rane, A., Love, A., & Kennedy, R. L. (2007) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610701667338 · Cited by 87
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw068 · Cited by 74
Schindler, C. W., Redhi, G. H., Vemuri, K., Makriyannis, A., Le Foll, B., Bergman, J., Goldberg, S. R., & Justinova, Z. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.27 · Cited by 73
Obesity Research—Limitations of Methods, Measurements, and Medications
Simons-Morton, D. G. (2006) · JAMA · doi:10.1001/jama.295.7.826 · Cited by 70
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Scheen, A. J. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01681.x · Cited by 68
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Eleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807120200 · Cited by 53
Horbach, T., Thalheimer, A., Seyfried, F., Eschenbacher, F., Schuhmann, P., & Meyer, G. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1620-z · Cited by 51
Atkinson, T. J. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00412.x · Cited by 49
Is there evidence for a set point that regulates human body weight?
Müller, M. J., Bosy-Westphal, A., & Heymsfield, S. B. (2010) · F1000 Medicine Reports · doi:10.3410/m2-59 · Cited by 49
Androgens, Obesity, and Sleep-Disordered Breathing in Men
Liu, P. Y., Caterson, I. D., Grunstein, R. R., & Handelsman, D. J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.002 · Cited by 43
Jørgensen, A. W., Lundstrøm, L. H., Wetterslev, J., Astrup, A., & Gøtzsche, P. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111964 · Cited by 40
Crater, G. D., Lalonde, K., Ravenelle, F., Harvey, M., & Després, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15353 · Cited by 41
al'Absi, M., & Allen, A. M. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.687106 · Cited by 34
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
Sathyapalan, T., Cho, L. W., Kilpatrick, E. S., Coady, A., & Atkin, S. L. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03345.x · Cited by 11
Fabbrini, E., & Klein, S. (2008) · Clinical Cornerstone · doi:10.1016/s1098-3597(08)60027-7 · Cited by 9
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Metadata
- Authors
- Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-02-15
- Volume
- 295
- Issue
- 7
- Pages
- 761
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1991778481
- Cited by
- 1,218
- References
- 27
- FWCI
- 125.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.